MacroGenics
MGNX
$4.36
Share price
-14.75%
Change (1 day)
-28.44%
Change (1 year)
Categories
MacroGenics (MGNX) - Cash on Hand
Cash on Hand as of December 2023 : $0.22 B
According to MacroGenics's latest financial reports the company has $0.22 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
MacroGenics - Cash on Hand chart (from 2012 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $0.22 B | 48.89% |
| 2022-12-31 | $0.15 B | -36.64% |
| 2021-12-31 | $0.24 B | -10.61% |
| 2020-12-31 | $0.27 B | 26.31% |
| 2019-12-31 | $0.21 B | -7.35% |
| 2018-12-31 | $0.23 B | -23.68% |
| 2017-12-31 | $0.30 B | 10.15% |
| 2016-12-31 | $0.27 B | -18.3% |
| 2015-12-31 | $0.33 B | 115.14% |
| 2014-12-31 | $0.15 B | 35.29% |
| 2013-12-31 | $0.11 B | 143.97% |
| 2012-12-31 | $47.74 M | -13.54% |
| 2011-12-31 | $55.21 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $12.69 B | 5,422.07% | 🇺🇸 USA |
 Eli Lilly LLY | $2.58 B | 1,025.43% | 🇺🇸 USA |
 Amgen AMGN | $10.94 B | 4,662.30% | 🇺🇸 USA |
 Gilead Sciences GILD | $7.26 B | 3,060.94% | 🇺🇸 USA |
 Merck MRK | $7.09 B | 2,986.53% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $9.67 B | 4,107.92% | 🇺🇸 USA |
 Xencor XNCR | $0.59 B | 158.36% | 🇺🇸 USA |